US 11,980,632 B2
Antiviral composition containing fucosyllactose as active ingredient
Dae Hyuk Kweon, Seoul (KR); Seok Oh Moon, Gwacheon-si (KR); Jung Hee Moon, Suwon-si (KR); Chul Soo Shin, Suwon-si (KR); Jong Won Yoon, Seongnam-si (KR); Seon Min Jeon, Daegu (KR); Young Ha Song, Yongin-si (KR); and Jong Gil Yoo, Suwon-si (KR)
Assigned to ADVANCED PROTEIN TECHNOLOGIES CORP., Suwon-si (KR)
Filed by ADVANCED PROTEIN TECHNOLOGIES CORP., Suwon-si (KR)
Filed on Nov. 23, 2022, as Appl. No. 17/993,760.
Application 17/993,760 is a continuation of application No. PCT/KR2021/018556, filed on Dec. 8, 2021.
Claims priority of application No. 10-2020-0173106 (KR), filed on Dec. 11, 2020.
Prior Publication US 2023/0114000 A1, Apr. 13, 2023
Int. Cl. A61K 31/702 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/702 (2013.01) [A61P 31/14 (2018.01)] 2 Claims
 
1. A method for treating a viral infection, comprising administering a composition comprising 3-fucosyllactose as an active ingredient to a subject in need thereof,
wherein the viral infection is an infection with coronavirus.